The decision to start HRT gets extensive clinical attention; the decision to stop gets far less. For women who have been using HRT for years, the practical questions are: what will happen when they stop, does it matter how they stop, and when is the right time?

The evidence on these questions is more specific than most clinicians communicate, particularly on the trajectory of symptom return, the limited role of tapering, and which protective effects reverse quickly versus slowly after stopping.

Symptom Return After Stopping

The most consistent finding across studies is that the majority of women who discontinue HRT after long-term use experience a return of vasomotor and other menopausal symptoms.

A follow-up study of women who stopped HRT after long-term use found that 93% experienced symptom recurrence within the first year of stopping.[1] Sleep disturbances (52%), vasomotor symptoms (45%), and mood changes were the most commonly reported. By three years after stopping, however, the majority of women were asymptomatic.[1]

That three-year trajectory matters. The return of symptoms after stopping HRT does not mean they will be permanent. For most women, the body reaches a new hormonal equilibrium and symptoms diminish over one to three years.

Tapering Versus Abrupt Discontinuation

Whether to taper gradually or stop abruptly is the most common practical question. The research is mixed.

Four randomised controlled trials have directly compared gradual tapering with abrupt discontinuation.[2][3] The findings split evenly:

  • Two studies found that women who stopped abruptly had more severe symptoms in the immediate weeks following discontinuation, but that severity equalled the tapering group once the tapering period was complete. Tapering delayed symptoms rather than preventing them.
  • Two studies found no measurable difference in symptom severity or frequency between the two approaches at any time point.

The most cited study concluded directly that gradual discontinuation of hormone therapy merely postpones, and neither prevents nor minimises, the reappearance of vasomotor symptoms, mood deterioration, and sexual dysfunction.[2]

Despite this, most clinicians recommend tapering. This reflects reasonable caution where the evidence is uncertain: there is no evidence tapering is worse, and for women anxious about discontinuation, a gradual process may be preferable. The clinical implication is that women choosing to taper should not interpret a smoother first few weeks as evidence they have escaped the rebound; the same symptoms typically emerge once the taper is complete.

What Protection You Lose

HRT's protective effects on long-term health outcomes are maintained while treatment continues and reduce after stopping.

Bone density. Gains or preservation achieved during HRT use are partially or fully lost in the years following discontinuation. The rate of bone loss after stopping is faster than age-related rates for approximately one to two years post-cessation before returning to the expected background trajectory.[4] Women using HRT specifically for osteoporosis prevention should discuss whether to transition to an alternative bone-protective medication rather than simply stopping.

Cardiovascular protection. The cardiovascular benefit of HRT started early in the menopausal transition (within the first ten years after menopause or before age 60, as established by the WHI and ELITE trials) is tied to maintaining vascular health during the window when estrogen normally provides that support. After stopping, cardiovascular risk returns to the trajectory expected without HRT: not a sudden increase, but the gradual removal of protection accumulated during that critical window.

Genitourinary tissue. GSM symptoms managed by the estrogen component of HRT will typically return after stopping systemic treatment. Local vaginal estrogen is separate from systemic HRT and can be continued indefinitely to maintain genitourinary health regardless of whether systemic HRT continues.

When Stopping Makes Sense

There is no universal time limit on HRT use. Current guidelines from NAMS, NICE, and the British Menopause Society state that duration should be individualised based on the woman's reasons for using it, her risk profile, and her preferences; HRT should not be stopped at an arbitrary age or after a fixed number of years solely as a precautionary measure.

Common reasons to consider stopping:

Symptoms have resolved. For a woman who started HRT in early perimenopause for severe vasomotor symptoms and is now several years postmenopause, a trial off HRT is reasonable to assess whether symptoms have naturally resolved. Many women find they are asymptomatic after stopping.

Risk profile has changed. A new diagnosis, change in family history, or significant cardiovascular event may alter the risk-benefit calculation. These decisions should be made with a clinician.

Personal preference. Patient preference is a legitimate reason to stop, and it warrants the same clinical rigour as any other indication. The conversation should cover expected symptom trajectory, which protective effects will diminish and on what timescale, and whether non-hormonal alternatives are appropriate, so the decision is made with a full picture rather than a general reassurance that stopping is safe.

How to Stop

If you and your doctor decide to stop, the three practical considerations (how to reduce the dose, how to manage symptoms during the transition, and what to maintain locally) are best approached together rather than sequentially.

Tapering over two to three months is a reasonable starting point, whether by reducing dose, switching to a lower-strength preparation, or reducing days per week. Alongside this, plan for behavioural support during the transition: pelvic floor exercises, cool bedding, and CBT-I for sleep can reduce symptom burden without additional medication. Non-hormonal pharmacological options (fezolinetant, SSRIs, or gabapentin) are available if vasomotor symptoms become significant and the decision to stay off systemic HRT holds. If GSM was a problem on systemic therapy, continue local vaginal estrogen; stopping systemic HRT does not require stopping local vaginal treatment, and the two are clinically independent.

Arrange follow-up. If symptoms are severe three months after stopping, the conversation about resuming should remain open.

References

[1] Ockene, J. K., Barad, D. H., Cochrane, B. B., et al. (2005). Symptom experience after discontinuing use of estrogen plus progestin. JAMA, 294(2), 183-193. See also: Menopausal symptoms after cessation of hormone replacement therapy. https://pubmed.ncbi.nlm.nih.gov/16051451/

[2] Aslan, E., Bagis, T., Killic, G. S., Sofuoglu, K., Esen, O., Tarim, E. (2007). How best is to discontinue postmenopausal hormone therapy: immediate or tapered? Maturitas, 56(1), 78-83. https://pubmed.ncbi.nlm.nih.gov/17046182/

[3] Biglia, N., Maffei, S., Lello, S., Nappi, R. E. (2010). Tibolone in postmenopausal women: a review based on recent randomized controlled clinical trials. Gynecological Endocrinology, 26(11), 804-814. See also: A randomized controlled study of taper-down or abrupt discontinuation. https://pubmed.ncbi.nlm.nih.gov/19675505/ Note: tibolone is a synthetic steroid with distinct pharmacology from conventional estrogen-progestogen HRT; findings on tapering should be interpreted with that difference in mind.

[4] Greendale, G. A., Espeland, M., Slone, S., Marcus, R., Barrett-Connor, E. (2002). Bone mass response to discontinuation of long-term hormone replacement therapy. Archives of Internal Medicine, 162(6), 665-672. https://doi.org/10.1001/archinte.162.6.665